Drugmakers should work together to get U.S. Food and Drug Administration (FDA) qualification for drug development tools (DDTs), which can then be used to aid in development and review of multiple companies’ drugs, a new draft guidance advises.
Simplifying Global Compliance
US FDA Draft Guidance Explains New Drug Development Tools
International Pharmaceutical Regulatory Monitor
